CLVT CLARIVATE PLC Insider Trading

President of A&G Veinstein Bar sold 309,902 shares of CLVT at $3.74 on 2025-12-01; stock now $3.68, -36.8% from 52-week high.

Veinstein Bar, President of A&G at Clarivate, sold 309,902 shares valued at $1,159,033.48, reducing holdings by 26.7% to 848,811 shares. The sale occurred at $3.74, and the stock has since declined to $3.68, sitting -36.8% below its 52-week high of $5.82. His cross-ticker track record shows a 100.00% well-timed rate on 1 prior sell, and at CLVT specifically, he executed a prior sale on 2024-09-19 that delivered -28.6% over 90 days, demonstrating consistent downside capture timing. Set against Clarivate's deteriorating fundamentals—net income of $-28,300,000.00 on revenue of $623,100,000.00, negative annual revenue growth of -2.7%, and ongoing unprofitability—this large, discretionary reduction of holdings aligns with his historical pattern of selling ahead of weakness and underscores the company's challenged financial position.

Director Kenneth L. Cornick bought 100,000 shares of CLVT at $3.45; 3rd purchase in 10 days as stock down 39.9% from 52-week high.

Cornick purchased 100,000 shares at $3.45, bringing his total holdings to 1,100,000 shares, representing a 10.0% increase from pre-transaction holdings. This is his third purchase at CLVT in the past 10 days (prior buys on 2025-11-03 and 2025-10-31), suggesting sustained accumulation activity at depressed levels. The current stock price of $3.50 is -39.9% from the 52-week high of $5.82, and the company reported negative net income of $-28,300,000.00 on revenue of $623,100,000.00, indicating ongoing unprofitability. Notably, Cornick's prior buy at this ticker on 2025-08-01 exhibited a 90-day return of -13.4%, and across his full cross-ticker open-market history, his 3 prior buys averaged a 90-day return of -13.4% with a 0.00% 90-day win rate, providing limited precedent for successful timing on similar accumulation patterns.

Director Cornick buys 725,000 shares in 2 transactions for $2,482,000 ($3.38–$3.52), raising stake 263.6% to 1M shares.

Kenneth L. Cornick, a Director at Clarivate, executed two open-market purchases totaling 725,000 shares (725.0K shares) for $2,482,000.00 at an average price of $3.42, materially increasing his holdings from 275,000 shares to 1,000,000 shares. The current price of $3.54 is 46.4% below the 52-week high of $6.61, and the stock has declined 9.0% over the past 30 days. Cornick's cross-ticker track record shows limited prior buy activity (1 prior buy with negative 90-day returns), and his only prior purchase at CLVT on 2025-08-01 also posted a -13.4% return over 90 days, indicating a pattern of ill-timed accumulation at this ticker. The company remains unprofitable, with a negative net income of $-28,300,000.00 in its most recent quarter and annual revenue contraction of -2.7%, providing limited fundamental support for the insider's enlarged position.

Director Snyder buys 1,460,000 CLVT shares at $3.33, boosting stake 185.4% to 2.25M; stock down 46.4% from 52-week high, company unprofitable.

Andrew Miles Snyder (Director) purchased 1,460,000 shares at $3.33 on 2025-10-31, increasing his holdings by 185.4% from 787,510 to 2.25M shares at a total cost of $4,861,800.00. The purchase occurred when CLARIVATE's stock is down 46.4% from its 52-week high of $6.61 and the company is unprofitable (net income of $-28,300,000.00 on revenue of $623,100,000.00). His prior purchases at CLVT have shown mixed results: a March 2025 buy resulted in 30d -21.1%, a purchase on 2024-08-09 showed 30d +17.6%, and a 2024-08-08 buy showed 30d +21.5%. Across his broader trading history, his 3 prior buys average 90d return of -9.0% with a 33.33% win rate, and his CLVT timing pattern shows only 1 of 3 prior buys were well-timed at the 90-day mark, suggesting inconsistent execution even when purchasing at lower valuations.

Director Kenneth L. Cornick purchases 165,000 shares of CLVT at $3.74; stock -48.0% from 52-week high, company unprofitable.

Kenneth L. Cornick, a director at Clarivate, purchased 165,000 shares at $3.74, increasing his holdings by 150.0% to 275,000 shares total. The transaction occurs against a backdrop of material headwinds: the stock trades -48.0% from its 52-week high of $7.10, has declined 30 days (-16.0%) and 90 days (-11.7%), and the company reported a net loss of $-72,000,000.00 in the latest quarter with full-year revenue down 2.7% year-over-year. Clarivate's market cap stands at $2,480,488,346.16 with an unprofitable fiscal year. Cornick's cross-ticker track record shows 10 prior open-market sells with an average 90-day return of -16.7%, and a well-timed sell rate of 100.00%, though this insider has no measurable prior same-ticker transaction history to establish predictive relevance for CLVT specifically. The timing of this purchase—into weakness and amid ongoing unprofitability—merits attention, particularly given the company's deteriorating financial trajectory and whether this reflects access to non-public improvement signals or simply reflects opportunistic positioning in a depressed price environment.

Director Andrew Miles Snyder buys 237.2K CLVT shares at $4.17; holdings up 43.1% to 787.5K shares

Director Andrew Miles Snyder purchased 237,176 shares of Clarivate at $4.17 on 2025-03-14, increasing his holdings by 43.1% from 550,334 to 787,510 shares. The stock trades at $4.31 currently, down 12.0% over the past 30 days and down 43.7% from its 52-week high of $7.65. His prior two purchases at Clarivate in August 2024 showed mixed near-term results (30d returns of +17.6% and +21.5%) but both declined 90 days later (−17.5% and −12.6%), with a 0% win rate at the 90-day horizon for this ticker. Meanwhile, the company remains unprofitable with negative net income of −$65.6M on quarterly revenue of $622.2M, and has contracted annually by 2.7%. The sustained accumulation despite deteriorating fundamentals and persistent 90-day underperformance in his prior Clarivate purchases warrants tracking how conviction in this position is validated or contradicted by upcoming quarterly results and near-term price action.

Director Bomba Jane L Okun purchased 49,750 shares of CLVT at $4.03; 3 other insiders also bought in 14 days

Director Okun initiated a position with a purchase of 49,750 shares at $4.03 on 2025-03-12, representing her first holding in the company. The transaction occurs within a cluster buy pattern, as 3 other insiders also purchased shares within the past 14 days. The timing coincides with significant stock weakness: the current price of $4.13 is -46.0% from the 52-week high of $7.65, and the 90-day change shows -19.2%. The company reported a net income of $-65.6M on quarterly revenue of $622.2M and is unprofitable on a full-year basis. The concurrent purchases by multiple insiders, combined with the stock's depressed valuation relative to its 52-week range, merit closer examination of whether these transactions reflect forward-looking information or simply an opportunistic accumulation at lower prices in a distressed financial environment.

Director Pritchett buys 22,857 shares of CLVT at $4.38 as stock down 46.3% from 52-week high; company unprofitable.

Wendell E. Pritchett (Director) purchased 22,857 shares at $4.38 on 2025-03-03, increasing his holdings by 46.7% from 49.0K to 71.8K shares in a $100.1K transaction. The purchase occurs against a backdrop of material weakness: the current price of $4.11 sits 46.3% below the 52-week high of $7.65, with the stock down 28.0% over 90 days and 21.0% over 30 days. Clarivate's fundamental position adds context—the company reported a net loss of $65.6M on quarterly revenue of $622.2M and is unprofitable on a full-year basis, with annual revenue declining 2.7% year-over-year. A director's discretionary purchase of meaningful size during acute price weakness in an unprofitable company warrants investor attention to underlying strategic or operational developments.

Director Saurabh Saha purchases 58,275 shares of CLVT at $4.36 amid -46.3% decline from 52-week high; post-purchase stake doubles to 82,016 shares

Director Saurabh Saha acquired 58,275 shares at $4.36 on 2025-03-03, more than tripling his prior 23,741-share position to 82,016 shares, representing a $254,079 open-market purchase. The transaction occurred as the stock trades -46.3% below its 52-week high and -21.0% over the past 30 days, amid fundamental headwinds: Clarivate reported a net loss of $-65.6M on revenue of $622.2M in its latest quarter, with full-year net income negative and annual revenue declining -2.7%. Saha's cross-ticker track record shows 16 prior open-market sells with a 60.00% well-timed rate, but this buy cannot be evaluated against his prior sell timing since it is a buy transaction. The magnitude of the purchase (245.5% increase in holdings) at a depressed price level warrants monitoring of whether this reflects management's assessment of valuation or strategic necessity amid the company's current operating losses.

Director Angelakis purchases 3.46M shares in 3 tranches for $17.9M (avg $5.16) at unprofitable Clarivate amid stock -44.4% from 52-week high.

Michael J Angelakis, a director at Clarivate PLC, executed three separate purchases totaling 3,465,000 shares for $17,863,350.00 across November 20–22, 2024, with a blended average price of $5.16. This represents a substantial new position (pre-transaction holdings were 0 shares) accumulated at prices between $5.11 and $5.19. The timing of this multi-day acquisition occurs while the stock trades at $5.25, down 44.4% from its 52-week high of $9.44 and down 19.6% over the past 30 days. Notably, the company reported negative net income of $-65,600,000.00 in its latest quarter and was unprofitable over its most recent full fiscal year, while revenue declined 1.2% year-over-year. A director's initiation of a multi-million-dollar position in a fundamentally challenged business during a severe drawdown invites investor scrutiny regarding both the director's conviction about recovery prospects and the strategic rationale for accumulation at this juncture.